Introduction
============

Of the different forms of apolipoprotein E (ApoE 2, 3, and 4), ApoE4 has a deleterious role in ischemic brain injury and is associated with a worse response and poorer long-term outcome in response to acute focal ischemic stroke, transient global ischemia, and hemorrhage ([@bib11], [@bib12]; [@bib36]). Possession of an *APOE*-*ɛ*4 allele is also associated with a deleterious influence on cognitive aging and is the major genetic risk factor for Alzheimer\'s disease ([@bib35]). Although the underlying mechanism for the deleterious effect of ApoE4 is not yet known, there are strong links between ApoE4 and mitochondrial dysfunction that might explain a general influence of ApoE4 on injury and disease. Mitochondria are critical in regulating normal neuronal functions and are disrupted in injury and disease ([@bib24]), often influenced by the presence of *APOE*-*ɛ*4. Notably, one of the earliest features detectable in the brains of young and elderly *APOE*-*ɛ*4 individuals ([@bib6]) is regional cerebral hypometabolism, a reflection of reduced mitochondrial function. This regional hypometabolism is further exacerbated in disease in *APOE*-*ɛ*4 carriers ([@bib25]). Transgenic *APOE*-*ɛ*4 mice also exhibit structural ([@bib37]) and functional ([@bib38]; [@bib5]) mitochondrial abnormalities. It has also been shown that there are structural and subsequent biophysical differences between ApoE protein isoforms, which may explain differential influences on mitochondrial function ([@bib13]). The structural conformation of ApoE4 ensures more efficient neuronal proteolytic cleavage compared with ApoE2 or ApoE3 with generated ApoE4 fragments causing neurodegeneration and cognitive deficits in transgenic mice ([@bib10]). There is direct evidence from *in vitro* cell-culture studies that overexpression of a truncated ApoE4 fragment, localizes to mitochondria and impairs mitochondrial function ([@bib4]). Similarly, a number of mitochondrial proteins have been identified as ApoE4-binding partners from cytosolic and membrane fractions of mouse brain ([@bib28]). Thus, ApoE isoforms may have differential effects on mitochondrial function that, in the presence of ApoE4, could render mitochondria susceptible to the effects of brain injury.

At present, the protein signature of mitochondria in different *APOE* genotypes is not known and is important as it could provide a basis on which to further explore biological differences between the different ApoE isoforms. To address this, we used liquid-chromatography mass spectrometry (LC-MS), which permits the quantitative assessment of large numbers of proteins simultaneously in brain tissue samples, and obtained a measure of mitochondrial proteins at baseline and in response to an ischemic challenge in *APOE*-*ɛ*3 and *APOE*-*ɛ*4 transgenic mice. The data demonstrate that not only is the protein signature different between ApoE isoforms at basal conditions but that there is a differential response of these proteins in response to injury.

Materials and methods
=====================

*APOE* Transgenic Mice
----------------------

*APOE*-*ɛ*3 and *APOE*-*ɛ*4 transgenic mice were produced as described previously ([@bib42]). Briefly, *APOE* knockout mice were generated by inactivating the endogenous *APOE* gene. Cosmid libraries were constructed from lymphoblasts of humans who were homozygous for *APOE*-*ɛ*3 and *APOE*-*ɛ*4. Fragments containing human regulatory sequences and the coding sequences for human *APOE* (*ɛ*3 and *ɛ*4) were isolated and injected into single-cell embryos from homozygous *APOE*-deficient mice and transferred to female recipients (a cross of C57BL/6J × DBA/2J) to produce founder transgenic mice. Founder mice were backbred to *APOE* knockout mice to produce mice hemizygous for human *APOE* transgenes and homozygous for inactivated mouse *APOE* gene. Animals were bred to homozygosity for human *APOE* transgenes and backbred into *APOE* knockout strains to remove the genetic influence of DBA/2J background strains. The presence of human *APOE* was confirmed by PCR. The mice were backcrossed at least 10 times to C57BL/6J mice in the USA before transport to Edinburgh, UK and thereafter several backcrosses to C57BL/6J were made. For the present study, the *APOE*-*ɛ*3-437 and *APOE*-*ɛ*4-81 lines were used, which carry two copies of the respective transgenes and are best matched for ApoE levels from the original lines bred ([@bib42]). All procedures were authorized under the Home Office approved project license number 60/3722. This license was approved by the University of Edinburgh\'s Ethical Review Committee and the Home Office and adhered to regulations specified in the Animals (Scientific Procedures) Act (1986). Mouse genotype was confirmed by PCR ([@bib12]).

Transient Global Ischemia
-------------------------

Adult, male mice were initially anesthetized with 5% isofluorane with oxygen, and maintained in 1.5% isofluorane. Temperature was monitored using a rectal probe and controlled to 37±0.5°C. A midline cervical incision was made and both common carotid arteries exposed and isolated using 4/0 silk thread. The common carotid arteries were occluded using microaneurysm clips applied bilaterally for 20 minutes. The duration of ischemia was based on previous observations, indicating that this duration was sufficient to induce ischemic neuronal damage in the caudate nucleus ([@bib12]; [@bib17]). After the period of occlusion, the clips were removed and blood flow through the arteries was confirmed before the incision was sutured closed (*n*=9, *APOE*-*ɛ*3 mice; *n*=9, *APOE*-*ɛ*4 mice). Sham-operated animals underwent an identical procedure except clips were not applied to the common carotid arteries (*n*=5, *APOE*-*ɛ*3 mice; *n*=6, *APOE*-*ɛ*4). The animals were placed in an incubator for 1 hour after which they were returned to the animal housing and allowed to recover. At 72 hours after treatment, the animals were deeply anesthetized with 5% isofluorane with oxygen, and perfused transcardially with buffered saline and the brain removed and halved. One hemisphere was fixed using 4% paraformaldehyde and then paraffin embedded for histological analyses. From the other hemisphere, the hippocampus was dissected out and used to prepare mitochondrial fractions. At the outset of the study, mice were coded and randomized for surgery with the operator blind to the genotype of the mice. The study was conducted with *a priori* hypothesis.

Hematoxylin and Eosin Staining to Determine Ischemic Damage
-----------------------------------------------------------

Paraffin-embedded sections (6 *μ*mol/L) were cut and stained with hematoxylin and eosin. The numbers of morphologically normal neurons and neurons showing features of ischemic cell change, defined by intense hematoxylin-stained pyknotic nuclei surrounded by eosinophilic cytoplasm, were counted in five randomly selected fields within the CA1 region of the hippocampus, using a 1-cm^2^ grid at × 400 magnification. The percentage of ischemic neurons was calculated for the area of interest.

Preparation of Mitochondrial Fractions
--------------------------------------

From each animal (*n*=29), mitochondrial fractions were prepared from a single hippocampus. Mitochondria were prepared from fresh tissue and all steps were performed on ice. Mitochondrial fractions were prepared using the Benchtop Mitochondria Isolation Kit for Rodent Tissue (Mitosciences, Eugene, OR, USA), generating two fractions: a mitochondrial fraction (M) and a postmitochondrial supernatant fraction (PM). The mitochondrial fraction is enriched in mitochondrial proteins, while the supernatant fraction is predominantly cytosolic, containing soluble and membrane-associated proteins. Protein concentrations of the fractions were determined using Pierce BCA assay.

Immunoblotting and Antibody Detection
-------------------------------------

Proteins were separated by SDS--PAGE and transferred onto PVDF membrane (GE Healthcare, Buckinghamshire, UK). Immunoblotting was performed using the Odyssey Infrared Imaging System (LiCor Biosciences, Lincoln, NE, USA). Membranes were blocked in Odyssey blocking buffer (diluted 1:1 with phosphate-buffered saline) and washed in phosphate-buffered saline--Tween (phosphate-buffered saline with 0.1% Tween). Primary antibodies were detected using fluorescently labelled secondary antibodies (LiCor Biosciences). Proteins were visualized by scanning antibody-labelled blots in the Odyssey Imager under the appropriate channel. Antibodies for western blotting were obtained from relevant manufacturer\'s: ApoE (Calbiochem, Darmstadt, Germany), COXI (Mitosciences, Eugene, OR, USA), COXIV (Cellular Signalling, Herfordshire, UK) and VDAC1 (AbCam, Cambridge, UK).

Analysis of Proteins from Immunoblots
-------------------------------------

Quantification was performed using the Odyssey image analysis program (LiCor Biosciences). In brief, the appropriate band was selected, background subtraction applied, and a resulting optical density (OD) value computed. To determine enrichment of mitochondrial markers (VDAC1, COXI, and COXIV), OD intensities were obtained from both mitochondrial and postmitochondrial fractions. These were used to determine the percentage of each protein in the mitochondrial fraction and allowed the assessment of mitochondrial integrity. For ApoE quantification, all raw OD values were normalized to recombinant ApoE3 (Chemicon, Watford, UK), loaded to enable intergel comparisons. This resulted in a normalized OD value (norm OD) that was analyzed statistically.

Liquid-Chromatography Mass Spectrometry Analysis of Mitochondria-Enriched Fractions
-----------------------------------------------------------------------------------

High-throughput proteomics using liquid chromatography in tandem with mass spectrometry has emerged as a valuable tool in understanding global protein expression without prior knowledge of the studied system (for recent review, see [@bib29]). To examine the proteomic response in *APOE* transgenic mice after ischemic injury, we conducted a quantitative analysis of the mitochondria-enriched fractions using a shotgun proteomic LC-MS approach coupled to a label-free analysis using MaxQuant software.

Four groups were analyzed with the number of animals within each group corresponding to that already examined for ApoE levels (ApoE3 sham *n*=5, ApoE3 global ischemia *n*=9; ApoE4 sham *n*=6, ApoE4 global ischemia *n*=9). All chemicals were purchased from Sigma-Aldrich (Gillingham, UK) unless otherwise stated. Acetonitrile and water for LC-MS/MS were HPLC grade (Fisher, Loughborough, UK). Formic acid was Suprapure 98% to 100% (Merck, Darmstadt, Germany) and trifluoroacetic acid was 99% purity sequencing grade. All HPLC-MS connector fittings were from Upchurch Scientific or Valco (Hichrom, Theale, UK and RESTEK, Saunderton, UK).

In all, 100 *μ*g of protein extract from mitochondrial fractions was resuspended in 12.5 *μ*L of 6 mol/L urea, 2.5 *μ*L of 200 mmol/L DTT, 2.5 *μ*L of 1 mol/L ammonium bicarbonate, and 1 *μ*L of 5% CHAPS. The samples were reduced at room temperature for 30 minutes then 2.5 *μ*L of 500 mmol/L iodoacetamide was added. Samples were diluted to 50 *μ*L, 2 *μ*g of trypsin was added and digested overnight. A fraction of the tryptically digested samples (10 *μ*g) was cleaned using an in-house SCX column (200 *μ*m × 6 cm) packed with 10 *μ*m PolySulfoethyl (Poly LC Inc., Columbia, MD, USA) as follows: SCX columns were conditioned with 100 *μ*L of 10 mmol/L potassium phosphate buffer (KPB), pH 3. Tryptic digests (5 *μ*L) were diluted with 45 *μ*L of 50 mmol/L H~3~PO~4~, 10% acetonitrile and loaded on the SCX column. SCX columns were washed with 40 mmol/L KPB, 10% acetonitrile and eluted with 75 *μ*L of 200 mmol/L ammonium bicarbonate.

Capillary-HPLC-MSMS data were collected on an online system consisting of a micropump (1,200 binary HPLC system, Agilent, Edinburgh, UK) coupled to a hybrid LTQ-Orbitrap XL instrument (Thermo-Fisher, Loughborough, UK). The LTQ was controlled through Xcalibur 2.0.7 and LTQ Orbitrap XL MS2.4SPI (Thermo-Fisher, Loughborough, UK). HPLC-MS methods have been described previously ([@bib20]). Peptides were reconstituted in 10 *μ*L of loading buffer before injection and 8 *μ*L was loaded. The peptide mixture was separated using a 2-hour gradient from 0% to 100% Buffer B (90% acetonitrile, 10% H~2~O, 0.025% trifluoroacetic acid, and 0.1% formic acid).

The mass spectrometer was operated in 'data-dependent mode,\' with a single MS scan (400 to 2,000 *m*/*z*) in FT mode 60K resolution followed by MS/MS scans in the linear ion trap on the three most abundant ions and dynamic excluded for 120 seconds.

Protein Identification and Quantification
-----------------------------------------

Conversion from RAW to MGF files was performed as described previously ([@bib20]). MS/MS data were searched using MASCOT Versions 2.3 (Matrix Science Ltd., London, UK) against a mouse plus contaminant IPI database with 55,413 sequences downloaded from <http://www.ebi.ac.uk> (version v3.42) and amended with the human ApoE and ApoE4 sequences due to the transgenic nature of the mouse model. Variable methionine oxidation, STY phosphorylation, protein N-terminal acetylation, and fixed cysteine carbamidomethylation were used in all searches. Precursor mass tolerance was set to 7 p.p.m. and MS/MS tolerance to 0.4 a.m.u. The significance threshold (*P*) was set \<0.05 (MudPIT scoring in Mascot). All LC-MS runs were combined using MaxQuant (version 1.0.13.8, Max Plank Institute of Biochemistry, Martinsried, Germany), assuming a false positive rate of 0.01. The MaxQuant output of protein group intensities, calculated as the sum of MS-peak intensities of identified peptides, was used as a relative abundance measure between samples. The data were converted using the Pride converter v2.4.2 ([@bib1]) and are available on the public data repository PRIDE (<http://www.ebi.ac.uk/pride/>; project 'Mouse APOE,\' accessions 15885 to 15913).

MaxQuant Label-Free Analysis Validation
---------------------------------------

The quantitation of relative protein abundance using MaxQuant was validated by spiking alcohol dehydrogenase (ADH *Saccharomyces cerevisiae*, Sigma, Gillingham, UK) into 10 mL HeLa cell extract (Dundee Cell, Dundee, UK, see [@bib20]). Spiked samples were analyzed back-to-back in 2-hour LC gradients. Three unspiked samples were run at the start, middle, and end of the queue to check for any carryover. The intensity of ADH in the unspiked samples was zero, indicating no carryover issues for ADH peptides. Spiked ADH concentrations were correlated with protein group intensities. A linear fit showed a positive correlation of spiked concentration with the protein group intensity computed by MaxQuant, with an *R*^2^ value of 0.992 (see [Figure 1](#fig1){ref-type="fig"}). This control experiment provides validation for the use of MaxQuant as a label-free analysis tool for the results presented below.

Bioinformatics Analysis
-----------------------

All proteins identified by LC-MS and Maxquant software (version 1.0.13.8) by at least two or more peptides were uploaded to the Database for Annotation, Visualization and Integrated Discovery (DAVID) (<http://david.abcc.ncifcrf.gov>; [@bib14]) to determine subcellular localization based on gene ontology (GO). The experimental interest and focus for this study were changes in the levels of mitochondrial proteins as a result of global ischemia in the context of two different *APOE* genotypes. Cognizant of the fact that mitochondrial preparations are enriched in, but are not exclusively mitochondrial proteins, proteins included in the GO term *mitochondrion* (GO:0005739) were identified from the master list, filtered out and subsequently analyzed statistically to determine differences in expression levels for this select protein pool.

Statistical Analysis
--------------------

Immunoblot data are presented as mean±s.e.m. Data were analyzed using GraphPad Prism version 5 (GraphPad Software Inc., La Jolla, CA, USA). Analysis of mitochondrial marker enrichment and quantification of ApoE levels from mitochondrial fractions were performed using two-way analyses of variance (ANOVAs) to allow simultaneous comparison between treatment groups (sham operated or global ischemia) and genotype (*APOE*-*ɛ*3 or *APOE*-*ɛ*4). *Post hoc* comparisons of two-way ANOVAs were made using *t*-test with Bonferroni correction unless otherwise noted. A value of *P*\<0.05 was considered to be statistically significant.

The primary statistical analysis for proteomic data focused on mitochondrial proteins only, as extracted from DAVID based on GO:0005739. Signal intensities of the mitochondria-associated proteins involved calculations with two-way ANOVA using the MultiExperiment Viewer: <http://www.tm4.org/mev/> ([@bib34]). Results of the two-way ANOVA are presented within functional categories (DAVID, Uniprot) along with the *F*-ratio for each factor of each protein found to have an *F*-ratio greater than the critical value of 7.77 (*P*\<0.01) with respect to *APOE* genotype, global ischemia or their interaction. A conservative probability was selected to reduce the rate of identifying false positives, but was relaxed slightly for network analysis (see below). Protein functions were determined primarily from annotations in Uniprot (<http://www.uniprot.org/>) and DAVID protein databases. For indicative purposes, selected biologically relevant proteins including human ApoE found to differ significantly by two-way ANOVA are presented with accompanying histograms along with results of *post hoc* comparisons using *t*-test with Bonferroni correction.

Network Analysis
----------------

Three separate data sets containing only proteins considered to be significantly affected by a given factor (*APOE genotype*, *global ischemia*, or their *interaction*) with *F*-ratio values \>4.24 were uploaded with their corresponding *P* values to Ingenuity Pathway Analysis (IPA) software. Protein identifiers were mapped to corresponding objects in Ingenuity\'s Knowledge Base. Networks were algorithmically generated based on direct relationships (physical interaction) between eligible proteins. The shading of network objects is negatively correlated with their *P* value. IPA generates a score which is putatively a measure of probability (but see [@bib7] for critical analysis) for the network.

Results
=======

Integrity of Mitochondrial Fractions
------------------------------------

Mitochondrial markers (VDAC1, COXI, and COXIV) were used to determine the enrichment of mitochondrial proteins in mitochondria fractions isolated from hippocampal tissue of *APOE* transgenic mice as well as their absence in postmitochondrial fraction supernatants ([Figure 2A](#fig2){ref-type="fig"}). VDAC1 is an outer mitochondrial membrane protein involved in metabolite diffusion, while both COXI and COXIV are components of the electron transport chain, located within the inner mitochondrial membrane. All three antibodies show presence of mitochondrial proteins in the enriched fraction. There was no significant effect of either ischemia or genotype on the percentage of VDAC1, COXI, or COXIV in the mitochondrial fraction ([Figure 2B](#fig2){ref-type="fig"}). None of these proteins were found in the postmitochondrial fractions. These data indicate there has been minimal breakdown of mitochondrial membranes during fractionation, and neither ischemia nor *APOE* genotype influence mitochondrial fractionation or integrity.

Genotype-Dependent Increase in Hippocampal Apolipoprotein E Levels of *APOE*-*ɛ*4 Transgenic Mice After Transient Global Ischemia
---------------------------------------------------------------------------------------------------------------------------------

Levels of full-length ApoE were measured by immunoblot in mitochondria-enriched fractions prepared from the hippocampus by immunoblot in shams and after ischemia. There were similar levels of ApoE in sham *APOE*-*ɛ*3 and *APOE*-*ɛ*4 mice. However in response to ischemia, there was a marked increase in ApoE levels in *APOE*-*ɛ*3 and *APOE*-*ɛ*4 transgenic mice ([Figure 3](#fig3){ref-type="fig"}). The levels of ApoE were significantly greater in *APOE*-*ɛ*4 as compared with *APOE*-*ɛ*3 mice after ischemia. Two-way ANOVA yielded a main effect for treatment (*F*(1, 25)=14.30, *P*\<0.001) and genotype (*F*(1, 25)=5.49, *P*\<0.05). No interaction effect was observed (*F*(1, 25)=3.02, *P*\>0.05). *Post hoc* comparisons identified that ApoE levels were significantly higher in *APOE*-*ɛ*4 mice with ischemic injury (2.5-fold higher) than in sham-operated *APOE*-*ɛ*4 mice (*P*\<0.001).

Ischemic Neuronal Damage in the Hippocampus
-------------------------------------------

The percentage of ischemic neuronal damage was assessed within the CA1 region of the hippocampus. In all sham-operated *APOE*-*ɛ*3 and *APOE*-*ɛ*4 transgenic mice, there was no ischemic neuronal damage. Transient global ischemia for 20 minutes led to minimal neuronal damage in the hippocampus of *APOE*-*ɛ*3 and *APOE*-*ɛ*4 transgenic mice (*APOE*-*ɛ*3 1.5±1.0%, *APOE*-*ɛ*4 1.6±1.2% ischemic neuronal damage), with no significant difference between genotypes (*P*=0.50). The low level of histological damage in the study limits definitive exploration of genotype influences (see [@bib12]).

Quantitative Proteomic Analysis of Mitochondria-Enriched Fractions
------------------------------------------------------------------

Using Maxquant software as a protein clustering and validation tool, and assuming a false positive rate of 0.01 based on a decoy database search, a total of 1,283 proteins were identified across all four groups, and of this, 1,067 were identified with a minimum of 2 peptides, the criterion for analytical inclusion (see [Supplementary Table 1](#sup1){ref-type="supplementary-material"} for full list of proteins).

LC-MS confirmed that human ApoE levels were significantly higher in mitochondrial fractions from *APOE*-*ɛ*4 transgenic mice after global ischemia ([Figure 4](#fig4){ref-type="fig"}). There was a significant effect of global ischemia on ApoE levels (*F*(1, 25)=4.798, *P*\<0.05) and a significant difference between *APOE*-*ɛ*4 mice with ischemic injury and sham-operated *APOE*-*ɛ*4 mice (*P*\<0.05), whereas in both sham groups ApoE was undetectable.

In all, 274 proteins were identified as mitochondria associated based on the GO designation *mitochondrion*, from the 1,067 analyzed using DAVID software (see [Supplementary Table 2](#sup1){ref-type="supplementary-material"} for full list of mitochondrial proteins). This distribution of mitochondrial versus nonmitochondrial proteins is in agreement with other published studies using similar mitochondrial preparations ([@bib9]). The categorization based on function and subcellular localization as determined by DAVID analysis for all the proteins identified is shown in [Figure 5](#fig5){ref-type="fig"} along with the functional annotation of the mitochondrial proteins.

In all, 12 of the 274 mitochondrial proteins were significantly altered (two-way ANOVA; *P*\<0.01) in relation to *APOE* genotype (two proteins: ETFA and ATP6V1A), *global ischemia* (five proteins: NDUFB5, CYB5B, HSPA1B, GLUL, and PHYHIPL), and *interaction* (five proteins: NDUFA11, NDUFS3, ATP5J, OXR1, and IARS2). Functional categorization of these proteins show a bias toward identifying changes in proteins involved in oxidative phosphorylation and stress (see [Table 1](#tbl1){ref-type="table"}).

Illustrative changes for some proteins found to have relevance to ischemia are shown in [Figure 6](#fig6){ref-type="fig"} ([@bib3]; [@bib17]). For example, marked increases in HSPA1B (HSP70) were observed in *APOE*-*ɛ*3 and *APOE*-*ɛ*4 mice after global ischemia. OXR1 was reduced in *APOE*-*ɛ*4 with global ischemia, but was not significantly different in *APOE*-*ɛ*3 mice. Certain patterns of protein expression are indicative of differential regulation in response to ischemic injury as a function of genotype.

Ingenuity Pathway Analysis Network Analysis
-------------------------------------------

IPA, applied judiciously, allows the synthesis of protein interactions from expansive protein lists and facilitates a better understanding of complex biological systems based on the creation of interactome networks. IPA network analysis was performed on three protein data sets referred to as *APOE genotype*, *global ischemia*, and *interaction* ([Table 1](#tbl1){ref-type="table"}) and comprising proteins with *F*-ratio values greater than the critical value of 4.17 (*P*\<0.05) and included 14, 18, and 27 proteins, respectively. Each network was scored and attributed functions (see [Figure 7B](#fig7){ref-type="fig"}).

Th*e APOE genotype* network (IPA score=23), generated from 14 proteins, was attributed the functions of 'cellular compromise, genetic disorder, and neurologic disease.\' The *APOE genotype* network included ETFA as a major hub protein as well as inner membrane components of complex 1 (NDUFB5 and NDUFB10), but required the insertion of multiple MT-ND family members as well as the hub proteins SNCA and HTT to allow for cohesion. The IPA score was substantially lower than the other 2 networks.

The *global ischemia* network (IPA score=31), generated from 17 proteins, was attributed the functions of 'cellular growth and proliferation, embryonic development and cell death.\' The *global ischemia* network included HSP1AB as a major hub protein and included multiple proteins involved in oxidative stress (e.g., PRDX1, SOD1, and HSPA1B).

The *interaction* network (IPA score=33), generated from 25 proteins, was attributed the functions of 'cardiovascular disease, genetic disorder, neurologic disease.\' The *interaction* network had the highest IPA score and like the *genotype* network includes components of complex 1, albeit different NDUF family members (NDUFA11 and NDUFS3), that appear to make up the core of the functional interactions. Distinct to this network are the 'peripheral\' proteins that are involved in various metabolic roles that are lacking in the other networks (e.g., DLAT, IVD, and ACADL).

Overall, in terms of significantly modulated mitochondrial proteins ([Table 1](#tbl1){ref-type="table"}), the effect of global ischemia had a slightly larger effect on mitochondria than *APOE* genotype. Moreover, after global ischemia, of those mitochondria-associated proteins found to be significantly altered within a given cohort, 73% are found to increase in *APOE*-*ɛ*3 transgenic mice compared with basal levels while only 19% are increased in *APOE*-*ɛ*4 mice ([Figure 7A](#fig7){ref-type="fig"}), indicating that mitochondria in *APOE* transgenic mice are responding differently to the stress of ischemic injury.

Discussion
==========

The present study demonstrates that not only are the levels of ApoE increased to a greater extent in mitochondria of *APOE*-*ɛ*4 mice as compared with *APOE*-*ɛ*3 mice, after an ischemic challenge, but that there are clear *APOE* genotype differences in the proteomic response of mitochondria in response to this challenge. The study additionally highlights that, even in the absence of injury, the proteomic signature is different between *APOE* genotypes.

ApoE isoform effects were investigated in response to a transient ischemic insult, which results in selective and delayed neuronal degeneration. In the mouse model used in this study and others ([@bib12]; [@bib17]), there is a regional hierarchy of damage such that the striatum exhibits a greater extent of damage as compared with the hippocampus. The extent of damage can be influenced by a number of variables notably, the duration of ischemia, temperature, and anesthetic. In the current study, in the hippocampus we detected minimal neuronal damage in response to transient global ischemia. Thus, our results reflect the hippocampal mitochondrial response in *APOE* transgenic mice to ischemic injury, and not overt neuronal cell death, with mitochondrial dysfunction a likely consequence of the ischemic insult. This work builds on our previous studies in which we demonstrated that ApoE levels are markedly increased in neurons in response to a severe ischemic injury with ApoE levels being greatest in *APOE*-*ɛ*4 compared with *APOE*-*ɛ*3 transgenic mice. This increase in ApoE parallels the more extensive hippocampal damage in *APOE*-*ɛ*4 as compared with *APOE*-*ɛ*3 mice in response to injury, suggesting that the increase in ApoE4 may be contributing to the cell death ([@bib12]). In the present study, the marked elevation of ApoE levels in mitochondria may be important to the pathogenic effect of ApoE4.

Previous studies have indicated structural and subsequent biophysical differences between ApoE protein isoforms which may explain differential influences on mitochondrial function ([@bib13]). The present study sought to identify whether the protein signature is different between *APOE* genotypes in the presence and absence of injury. We used mass spectrometry-based proteomic techniques that offer a powerful approach to identify and quantify proteins in a complex mixture. Label-free quantification requires neither prior knowledge nor labelling strategy, and protein expression is determined from peptide intensities ([@bib31]; [@bib39]; [@bib41]). The ADH spiking experiments (see [Figure 1](#fig1){ref-type="fig"}) validate the use of MaxQuant to quantitate relative protein abundance in our hippocampal fractions without the use of isotope labelling. Using this technique, we were able to identify 274 mitochondria-associated proteins from a total of 1,067 proteins identified with at least two peptides. Based on recent work suggesting there are 1,075 mitochondrial proteins in brain ([@bib18]), we have identified ∼26% of the 'complete\' mitochondrial proteome based on current GO annotation. Given our experimental design, with each sample subjected to a single round of LC-MS, in contrast to more comprehensive interrogations of the mitochondrial proteome ([@bib18]; [@bib27]), which typically use replicate analysis of the same sample or more complex protein fractionation methods before LC-MS analysis, we have detected a reasonable percentage of the mitochondrial proteome. Furthermore, the detection of human ApoE at levels that are reminiscent of earlier observed differences in ApoE levels within the immunoblot data lend credence to the use of label-free quantification techniques not only to identify proteins, but do so in different biological contexts, i.e., an ischemic challenge. In the present study, the largest functional category was identified as *mitochondrion* but other categories were identified including the *cytoskeleton* and *synapse*. ApoE is reported to have diverse roles within the central nervous system including regulation of synaptic plasticity and these other functions could be studied further using the present approach by isolation of different cellular compartments (e.g., synapses).

Our proteomic results show that under basal and injury conditions, *APOE* genotype has a differential effect on mitochondrial protein levels indicative of significant alterations in the regulation of energy production, metabolism, redox control/oxidative stress, and organelle dynamics ([Table 1](#tbl1){ref-type="table"}). One of the primary functions of mitochondria is energy production, with glucose the primary fuel for the brain. Glucose is converted into ATP via a number of metabolic reactions encompassing glycolysis, the pyruvate dehydrogenase complex, and tricarboxylic acid cycle, before oxidative phosphorylation and the subsequent generation of ATP. Although glycolysis generates ATP under basal conditions, and in particular in times of cellular stress, oxidative phosphorylation is the most efficient means of ATP production ([@bib23]); and therefore, neuronal function is critically dependent on oxidative phosphorylation, which itself is dependent on the efficient functioning of various metabolic pathways. In the present study, we were able to demonstrate that the isolated mitochondria remained relatively intact after cerebral ischemia as compared with those from control tissue allowing the identification of their proteomic signature. Within the isolated mitochondria, we were able to detect even small molecules (including cytochrome C) although these were not found to be significantly altered across the cohorts. In response to ischemia, it is recognized that dynamic alterations occur within mitochondria resulting in generation of reactive oxygen species and release of proteins such as cytochrome C and Smac, alterations in which we would not be able to detect in the preparation used (for review, see [@bib30]). Although we cannot directly correlate expression levels with enzyme activity, assumptions can be made of the functional capacity of the affected mitochondria.

Approximately the same number of proteins, albeit distinctly different proteins, categorized as being functionally involved in oxidative phosphorylation, are affected by *genotype*, *global ischemia,* or *interaction* as seen in the respective data sets in [Table 1](#tbl1){ref-type="table"}. The lack of congruency is suggestive of differential regulation of key inner mitochondrial proteins. For example, NDUFA11 is increased in *APOE*-*ɛ*3 mice after global ischemia (see [Figure 6](#fig6){ref-type="fig"}), but is decreased in *APOE*-*ɛ*4 after the same insult, leading to a relatively high *F*-ratio (19.75) for the interactive effect of both genotype and ischemia on this component of complex 1 of the electron transport chain (*P*\<0.01). Various other proteins located within the inner mitochondrial membrane were also found to be significantly modulated across the groups. Many of these, like NDUFA11 are found within the electron transport chain (e.g., NDUFB5, NDUFB10, and COX7A2) and are major components of the *genotype* and *interaction* functional networks ([Figure 7B](#fig7){ref-type="fig"}). Others are involved in protein/ion transport across the inner membrane (e.g., TIMM10, TIMM13, and SLC25A11; [@bib21]; [@bib16]) and are differentially expressed across the different cohorts in similar ways. These data may suggest that the inner mitochondrial dynamics of the two genotypes are fundamentally different. Increased expression of a truncated form of ApoE4 associated with mitochondrial dysfunction ([@bib4]) has been shown to reduce the activities of complex III and IV of the inner mitochondrial membrane ([@bib28]), and likewise, we see differential regulation of proteins that represent both complexes (e.g., UQCRH and Cox7a2, respectively).

Unsurprisingly, after the ischemic challenge, both *APOE*-*ɛ*3 and *APOE*-*ɛ*4 mice show modulation of proteins involved in oxidative stress, including HSPA1B (or HSP70), SOD1, OXR1, and PRDX1 ([@bib17]; [@bib15]; [@bib3]) but alterations in these proteins were *APOE* genotype dependent. For example, OXR1 which protects against oxidative damage and has been shown to be induced after oxidative stress ([@bib8]), is increased in *APOE*-*ɛ*3 mice after ischemia but is downregulated after ischemia in *APOE*-*ɛ*4 mice (see [Figure 6](#fig6){ref-type="fig"}). Similarly, PRDX1 was significantly increased in the *APOE*-*ɛ*3 mice after global ischemia, whereas no such change was seen in the *APOE*-*ɛ*4 mice. This may suggest a decreased capacity to respond to oxidative damage under basal conditions (increased expression in sham-operated *APOE*-*ɛ*4 compared with *APOE*-*ɛ*3 mice), with less effective protection afforded after ischemic injury (decreased expression in *APOE*-*ɛ*4 ischemic compared with sham mice). This is reflected in the *global ischemia* functional network as well, which comprising multiple proteins implicated in the cellular response to global ischemia and attributed the associated function of 'cell death.\'

Various metabolic proteins were also found to be altered, some of which can be found within the *interaction* functional network ([Figure 7B](#fig7){ref-type="fig"}) as 'peripheral\' nodes (e.g., PCCB, ACADL, and ACAT) and are involved in different facets of lipid metabolism vital for normal cell functioning. Other proteins (GLUL, HIBCH, AK1, and AK3) are involved in different aspects of energy metabolism. This suggests that *APOE* genotype has an effect on the metabolic capacity of the mitochondria after ischemia, which in turn may have downstream effects on ATP production.

IPA networks also indicated certain molecules that are potentially involved in the regulatory control of proteins that were found to be upregulated and downregulated as a result of either genotype or ischemia. This includes the transcription factor HNF4A, which appears in all three generated networks. This molecule as well as other inserted nodes allow for the generation of new hypothesis pertaining to mechanisms underlying pathology as well as how to potentially intervene.

Besides the efficient production of ATP by individual mitochondria, the proper distribution of mitochondria along the neuron is important to provide local ATP supplies as well as buffer calcium transients in both the synapse and dendrite ([@bib2]; [@bib22]). Therefore, the efficient transport of mitochondria along the neuronal cytoskeleton is critical. Disturbances to mitochondrial motility can impact on neuronal energy demands and viability ([@bib32]), which are shown to be disturbed in *APOE* transgenic mice ([@bib40]). RHOT1 and RHOT2 are two modulated proteins (*genotype* and *interaction,* respectively) identified with involvement in mitochondrial transport ([@bib19]; [@bib26]; [@bib33]). These changes may also have relevance to understanding potential apoE isoform differences in regulating aspects of synaptic plasticity.

Proteomic analysis has allowed us to identify functional pathways that are likely more susceptible to dysfunction in the context of a particular *APOE* genotype. Future studies could also elucidate whether the association between ApoE and mitochondria is direct or mediated through a secondary interaction, and if ApoE can translocate across the mitochondrial membrane. Additionally, it remains to be determined whether increases in ApoE levels or isoform are the main contributor to the pathogenic effect of ApoE4 after injury. Irrespective of this, the present study provides a basis on which to allow for further exploration into the mechanisms behind the differential regulation of mitochondrial function by ApoE isoforms.
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![Validation for the use of MaxQuant as a label-free analysis tool. Quantitation of relative protein abundance using MaxQuant was validated by spiking alcohol dehydrogenase (ADH Saccharomyces cerevisiae, Sigma) into 10 mL HeLa cell extracts. A linear fit showed a correlation of spiked ADH concentrations with the protein group intensity computed by MaxQuant, with an *R*^2^ value of 0.992.](jcbfm2011120f1){#fig1}

![Mitochondrial integrity of fractions. (**A**) Representative images of VDAC1, COX1, and COX1V immunoblots of sham and global ischemia apolipoprotein E (*APOE*)-*ɛ*3 and *APOE*-*ɛ*4 hippocampal tissue. The hippocampus of each was fractionated into mitochondrial (M) and postmitochondrial supernatant (PM) fractions. Mitochondrial proteins are detected in the mitochondrial fraction only as evident by detection of outer membrane marker VDAC1 or inner membrane markers COXI and COXIV. (**B**) The percentage of VDAC1, COXI, and COXIV measured in immunoblots in the mitochondrial fraction as compared with postmitochondrial fraction was calculated. Two-way analysis of variance (ANOVA) determined no significant effect of either treatment or *APOE* genotype.](jcbfm2011120f2){#fig2}

![Full-length ApoE protein is increased in mitochondrial fractions after global ischemia. Full-length apolipoprotein E (ApoE) was detected in immunoblots of mitochondria prepared from the hippocampus of *APOE* transgenic mice after global ischemia (*APOE*-*ɛ*3 *n*=9; *APOE*-*ɛ*4 *n*=9) or in sham-operated controls (*APOE*-*ɛ*3 *n*=5; *APOE*-*ɛ*4 *n*=6). ApoE is present as a doublet at 34 kDa. ApoE protein expression levels were quantified. *Post hoc* comparisons showing statistical significance are shown. ^\*\*\*^*P*\<0.001.](jcbfm2011120f3){#fig3}

![Liquid-chromatography mass spectrometry (LC-MS) detected increased apolipoprotein E (ApoE) protein intensity levels in mitochondrial fractions after global ischemia. ApoE was detected using LC-MS in mitochondria prepared from the hippocampus of *APOE* transgenic mice after global ischemia (*APOE*-*ɛ*3 *n*=9; *APOE*-*ɛ*4 *n*=9) or in sham-operated controls (*APOE*-*ɛ*3 *n*=5; *APOE*-*ɛ*4 *n*=6) using LC-MS. There was a significant effect of global ischemia. *Post hoc* comparisons showing statistical significance are shown. ^\*^*P*\<0.05.](jcbfm2011120f4){#fig4}

![Functional annotation of all identified proteins as well as mitochondrial proteins across all four cohorts. Functional groupings of identified proteins based on Database for Annotation, Visualization and Integrated Discovery (DAVID) analysis are shown in the top pie chart. Of the 1,067 proteins uploaded to DAVID, the largest functional category, including 274 proteins, was identified as *mitochondrion*. Further DAVID analysis of these 274 proteins is shown in the lower pie chart with the majority of identified proteins localized to the inner membrane.](jcbfm2011120f5){#fig5}

![Protein intensity levels of selected mitochondrial proteins significantly modulated as a result of global ischemia, apolipoprotein E (*APOE*) genotype, or both. Normalized peptide protein intensity levels of selected proteins across all four experimental cohorts are indicative of differential protein regulation. *Post hoc* comparisons are shown. ^\*^*P*\<0.05, ^\*\*^*P*\<0.01, ^\*\*\*^*P*\<0.001.](jcbfm2011120f6){#fig6}

![(**A**, **B**) Apolipoprotein E (*APOE*) genotype differential regulation of mitochondrial protein expression after global ischemia. (**A**) The percentage of upregulated and downregulated proteins in ApoE3 and ApoE4 transgenic mice after global ischemia (G) versus sham (S) indicates a differential regulation of protein levels. IPA network analysis was completed with proteins whose differential expression was a result of *APOE* genotype, global ischemia, or their interaction as determined by two-way analysis of variance (ANOVA). All proteins with an *F*-ratio value \>4.24 within a given category were included. Network scores are indicative of a more robust fit to a given network. (**B**) The top networks from each data category are presented. Blue shaded nodes are those proteins uploaded to IPA, whereas unshaded nodes have been inserted by IPA to create a network with a maximum number of 35 molecules. Only those molecules with direct relationships (physical interaction) indicated by solid edges were included in the analysis. IPA, Ingenuity Pathway Analysis.](jcbfm2011120f7){#fig7}

###### Altered mitochondrial proteins

  *IPI*         *Gene name*   F-*ratio (genotype)*   F-*ratio (global ischemia)*   F-*ratio (interaction)*   *Protein function*
  ------------- ------------- ---------------------- ----------------------------- ------------------------- ------------------------------------------------------
                                                                                                             *Oxidative phosphorylation/tricarboxylic acid cycle*
  IPI00318645   *Ndufa11*     2.06                   3.13                          **19.75**                  Complex I subunit
  IPI00132531   *Ndufb5*      **5.69**               **8.07**                      0.12                       Complex I subunit
  IPI00121288   *Ndufb10*     **4.33**               0.00                          1.91                       Complex I subunit
  IPI00121309   *Ndufs3*      0.55                   3.02                          **8.90**                   Complex I subunit
  IPI00129516   Uqcrh         0.16                   0.42                          **4.55**                   Complex III subunit
  IPI00111885   Uqcrc1        0.73                   **4.70**                      0.89                       Complex III subunit
  IPI00114377   *Cox7a2*      0.87                   0.38                          **5.60**                   Complex IV subunit
  IPI00230507   *Atp5h*       1.26                   0.59                          **7.34**                   Complex V subunit
  IPI00125460   *Atp5j*       0.00                   0.12                          **7.88**                   Complex V subunit
  IPI00453777   *Atp5d*       2.11                   0.12                          **4.69**                   Complex V subunit
  IPI00315794   *Cyb5b*       1.10                   **8.98**                      2.53                       Electron transport
  IPI00116753   *Etfa*        **10.33**              0.55                          1.84                       Electron transport
  IPI00261627   *Sucla2*      **5.01**               1.28                          0.33                       Tricarboxylic acid cycle enzyme
  IPI00323592   *Mdh*         0.55                   **4.69**                      3.48                       Tricarboxylic acid cycle enzyme
  IPI00230754   *Slc25a11*    **5.07**               0.56                          0.14                       Carrier protein
                                                                                                              
                                                                                                             *Reactive oxygen species* *control/oxidative stress*
  IPI00660262   *Gpx4*        0.10                   0.98                          **5.94**                   Antioxidant
  IPI00121788   *Prdx1*       0.03                   **6.85**                      0.57                       Antioxidant
  IPI00130589   *Sod1*        0.08                   **4.39**                      **4.70**                   Antioxidant
  IPI00117929   *Oxr1*        **5.80**               **7.64**                      **14.79**                  Protects from oxidative damage
  IPI00319518   *Lonp1*       **6.44**               **4.36**                      0.16                       Proteolysis of oxidized proteins
  IPI00346073   *Hspa1b*      0.74                   **24.26**                     0.74                       Chaperone protein
  IPI00229080   *Hsp90ab1*    2.04                   **5.94**                      0.41                       Chaperone protein
                                                                                                              
                                                                                                             *Other metabolic processes*
  IPI00626790   *Glul*        1.68                   **13.02**                     1.65                       Glutamate metabolism
  IPI00132593   *Gls2*        1.04                   0.02                          **4.40**                   Glutamine catabolism
  IPI00154047   *Hibch*       **5.15**               2.22                          **6.92**                   Amino-acid metabolism
  IPI00116222   *Hibadh*      **5.63**               0.59                          0.47                       Amino-acid metabolism
  IPI00227773   *Ppp1cc*      0.01                   3.16                          **5.30**                   Glycogen metabolism
  IPI00750256   *Ak1*         0.36                   **5.33**                      2.53                       ATP/ADP interconversion
  IPI00221769   *Ak3*         4.10                   3.02                          **6.14**                   AMP phosphorylation
  IPI00453499   *Iars2*       1.41                   1.68                          **7.86**                   Protein synthesis
                                                                                                              
                                                                                                             *Lipid metabolism*
  IPI00119114   *Acadl*       0.33                   0.00                          **4.25**                   Lipid metabolism
  IPI00154054   *Acat*        **5.11**               0.44                          2.31                       Lipid metabolism
  IPI00468653   *Pccb*        **5.36**               **5.36**                      **5.85**                   Lipid metabolism
                                                                                                              
                                                                                                             *Apoptosis*
  IPI00404551   *Ctsd*        1.85                   **6.46**                      1.80                       Protease/Apoptosis
                                                                                                              
                                                                                                             *Protein import*
  IPI00134484   *Timm13*      2.07                   **6.38**                      0.00                       Small transporter inner membrane complex
  IPI00165902   *Timm10*      2.96                   0.39                          **5.73**                   Small transporter inner membrane complex
                                                                                                              
                                                                                                             *Mitochondrial transport*
  IPI00515349   *Rhot1*       **5.09**               0.69                          2.22                       Attachment to microtubules
  IPI00473646   *Rhot2*       2.16                   3.20                          **4.31**                   Attachment to microtubules
                                                                                                              
                                                                                                             *Unknown mitochondrial function*
  IPI00115827   *Gbas*        0.09                   1.37                          **5.50**                   NipSnap family/vesicular transport
  IPI00407692   *Atp6v1a*     **8.14**               0.14                          0.01                       Subunit of V-ATPase/proton transport
  IPI00648312   *Nt5dc3*      2.37                   1.79                          **6.77**                   ?
  IPI00224093   *Phyhipl*     2.07                   **14.02**                     2.07                       ? Central nervous system development
  IPI00655156   *Ccdc109a*    **4.75**               1.15                          1.40                       Coiled-coil domain family
  IPI00331549   *Dhrs1*       1.33                   **4.82**                      0.66                       Oxidoreductase
  IPI00135106   *Mobp*        1.60                   0.08                          **7.30**                   Myelin sheath stability
  IPI00131614   *Sncb*        0.85                   0.03                          **5.59**                   ? Neuronal plasticity
  IPI00131896   *Brp44*       0.04                   0.09                          **4.41**                   ?
  IPI00153792   *Qil1*        0.16                   0.04                          **4.94**                   ?

The critical values *F* (1, 25) for *P*\<0.01 and *P*\<0.05 are 7.77 and 4.24, respectively. Of the 275 mitochondrial proteins, 12 presented here have *F* values \>7.77 in respect to genotype (2), global ischemia (5), or their interaction (5). All mitochondrial proteins with an *F* value \>4.24 for at least one comparison are included in the table and highlighted in bold. Proteins are presented in functional categories as they relate to mitochondrial function.

[^1]: These authors contributed equally to this work.
